Actuate Therapeutics (NASDAQ:ACTU) Now Covered by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of Actuate Therapeutics (NASDAQ:ACTU) in a report issued on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $20.00 price objective on the stock.

Actuate Therapeutics Stock Performance

Shares of ACTU stock opened at $7.40 on Monday. The business has a 50 day moving average of $8.16 and a two-hundred day moving average of $8.07. Actuate Therapeutics has a 52 week low of $5.51 and a 52 week high of $11.73.

Hedge Funds Weigh In On Actuate Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sigma Planning Corp acquired a new position in Actuate Therapeutics in the fourth quarter valued at approximately $128,000. Northwestern University acquired a new position in Actuate Therapeutics in the third quarter valued at approximately $207,000. Freestone Capital Holdings LLC acquired a new position in Actuate Therapeutics in the fourth quarter valued at approximately $80,000. OMERS ADMINISTRATION Corp acquired a new position in Actuate Therapeutics in the fourth quarter valued at approximately $84,000. Finally, BIOS Capital Management LP acquired a new position in Actuate Therapeutics in the fourth quarter valued at approximately $78,753,000.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.